Desmoid Tumors Market
- 2026 年市場規模
- USD 3,306.1 Mn
- 2033 年預估規模
- USD 5,413.9 Mn
- 年複合成長率 CAGR
- 7.3%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Desmoid Tumors Market, By Drug Type (Non-steroidal anti-inflammatory drugs(NSAIDs), Targeted Therapy, Chemotherapy, Hormone Therapy, Others), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
A desmoid tumor is an abnormal growth that arises from connective tissue, which is the tissue that provides strength and flexibility to structures such as bones, ligaments, and muscles. Desmoid tumors are fibrous, much like scar tissue. They are generally not considered cancerous (malignant) because they do not spread to other parts of the body. However, they can aggressively invade the surrounding tissue and can be very difficult to remove surgically. These tumors often recur, even after apparently complete removal. The most common symptom of desmoid tumors is pain. Other signs and symptoms, which are often caused by growth of the tumor into surrounding tissue, vary based on the size and location of the tumor.
Market Dynamics
Key players operating in the market are focused on developing drugs for the treatment of desmoid tumors which is expected to drive the market growth over the forecast period. For instance, in July 2022, Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focusing on discovering and commercializing small molecule medicines for patients with uncommon tumors and aggressive cancers, announced positive interim findings from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical study assessing AL102 in desmoid tumors. AL102 is an oral gamma-secretase inhibitor that is powerful and specific GSI. Moreover, the presence of desmoid tumor foundation providing funds for desmoid tumor research, is expected to drive the market growth in the country over the forecast period. For instance, Desmoid Tumour Foundation of Canada (DFC) is a registered Canadian charity dedicated to funding research for cure for desmoid tumors. DFC is dedicated to funding desmoid tumor research and finding a cure for this rare disease. DFC supports the collaboration between researchers from different institutions to expedite the development of cure.
Key features of the study
• This report provides an in-depth analysis of the global desmoid tumor market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global desmoid tumor market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies.
• Key companies covered as a part of this study Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Natco Pharma Ltd, Lupin, Zydus Lifesciences, Mylan N.V., Assertio Holdings, Inc., Mayne Pharma Group Limited, Alembic Pharmaceuticals Limited, Aprazer, Ayala Pharmaceuticals, SpringWorks Therapeutics, Inc., Iterion Therapeutics, Novartis AG, Apotex Inc., Bayer AG., Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd., Endo International plc, Abbott, and Getwell Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global desmoid tumor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Desmoid Tumors Market.
Market Segmentation
• By Drug Type (Revenue, USD Mn, 2021 - 2033)
o Non-steroidal anti-inflammatory drugs (NSAIDs)
o Targeted Therapy
o Chemotherapy
o Hormone Therapy
o Others
• By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Mn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
North Africa
Central Africa
South Africa
• Key Players
o Horizon Therapeutics Plc
o Strides Pharma Science Limited
o Teva Pharmaceutical Industries Ltd.
o Amneal Pharmaceuticals LLC
o Hikma Pharmaceuticals PLC
o Natco Pharma Ltd
o Lupin
o Zydus Lifesciences
o Mylan N.V.
o Assertio Holdings, Inc.
o Mayne Pharma Group Limited
o Alembic Pharmaceuticals Limited
o Aprazer
o Ayala Pharmaceuticals
o SpringWorks Therapeutics, Inc.
o Iterion Therapeutics
o Novartis AG
o Apotex Inc.
o Bayer AG.
o Sun Pharmaceutical Industries Ltd
o Reddy’s Laboratories Ltd.
o Endo International plc
o Abbott
o Getwell Pharmaceuticals
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Opportunity
o Impact Analysis
o Regulatory Scenario
o Market Trends
o Key Developments
o Epidemiology
o PEST Analysis
o Reimbursement Scenario
o Pipeline Analysis
o Collaboration Scenario
o Treatment Option Analysis
o Treatment Safety and Efficacy Analysis
o Site of Activity (Mode of Action)
o Treatment Algorithm for Desmoid Tumours
o Disease Awareness Programs
o Risk and Adverse effects
o Healthcare spending by Country
o Unmet Needs
o Treatment Rate
4. Global Desmoid Tumors Market, By Drug Type, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Non-steroidal anti-inflammatory drugs (NSAIDs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Targeted Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Chemotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Hormone Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Desmoid Tumors Market, By Distribution Channel, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Desmoid Tumors Market, By Region, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Horizon Therapeutics Plc
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Strides Pharma Science Limited
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Teva Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Amneal Pharmaceuticals LLC
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Hikma Pharmaceuticals PLC
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Natco Pharma Ltd
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Lupin
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Zydus Lifesciences
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Mylan N.V.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Assertio Holdings, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Mayne Pharma Group Limited
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Alembic Pharmaceuticals Limited
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Aprazer
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Ayala Pharmaceuticals
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
SpringWorks Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Iterion Therapeutics
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Novartis AG
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Apotex Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Bayer AG
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Sun Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Reddy’s Laboratories Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Endo International plc
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Abbott
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Getwell Pharmaceuticals
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
8. Section
o Research Methodology
o About us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們